ArticleClinical neurology and neurosurgery2025
Association of SSRI and SNRI use with incident hyponatremia after subarachnoid hemorrhage.
Article in Clinical neurology and neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundHyponatremia is common following subarachnoid hemorrhage (SAH) and is associated with vasospasm and delayed cerebral ischemia (DCI). Risk factors for post-SAH hyponatremia are poorly defined; however, selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs) are associated with hyponatremia in non-SAH populations. This study assessed whether pre-admission SSRIs/SNRIs were associated with hyponatremia after SAH.
methodsThis was a single-center retrospective study at a comprehensive stroke center. Patients were included if they were admitted for nontraumatic SAH (aneurysmal, perimesencephalic, or angiography-negative) and were excluded if they died within 24 h of presentation or were hyponatremic on admission. The primary endpoint was the incidence of hyponatremia. Key secondary endpoints included incidence of vasospasm, DCI, and rebleeding and discharge modified Rankin scale.
results292 patients were included; 49 patients were prescribed an SSRI or SNRI prior to admission. Of those included, 55.5 % had a Hunt and Hess score of 1 or 2, and 45 % of patients had anterior aneurysms. 11 % and 26 % of patients had perimesencephalic and CTA-negative SAH respectively. Hyponatremia occurred in 37 % of patients prescribed SSRIs/SNRIs vs 30 % of patients not on SSRIs/SNRIs (p = 0.36). Incidence of radiographic vasospasm in the SSRI/SNRI group was 33 % compared to 21 % in the non-SSRI/SNRI group (p = 0.065).
conclusionsWe did not find an association that reached our predefined statistical threshold between pre-admission SSRI/SNRI utilization and hyponatremia or secondary endpoints including vasospasm. This study suggests serotonergic therapies do not cause large effects on hyponatremia or clinically relevant complications after SAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.